InvestorsHub Logo
Followers 0
Posts 2
Boards Moderated 0
Alias Born 10/06/2017

Re: None

Friday, 10/06/2017 6:20:43 PM

Friday, October 06, 2017 6:20:43 PM

Post# of 5959
I spoke with Bob in IR.
I called him yesterday to ask specifically about the holdcos and Silenor OTC. This is what he said:

First of all he said he spoke with the CFO (Maio) he said legal counsel (Pina) may have more info but he wasn't available.

As far as the holdcos, he said they were a requirement from Hibridge Capitol as part of the debt restructuring. Each of the 3 core drugs were packaged into a holdco so loans could be taken against them. Specifically he used Zohydro as the example and said this was put into a holdco and it was used as collateral for securing the loan against it. Same with Silenor and Trex.

As far as Silenor OTC, he said the patents on the branded drug expire in 2020, the tentative plan (the company did not have an official plan) is to sell the drug as branded until close to the expiry of the patent then take it OTC. The company is expecting this to significantly open the market and will give them another 10 years of exclusivity. He did confirm all clinical studies are complete to demonstrate safety.

Let me know if you have any questions

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.